Show simple item record

dc.contributor.authorMartinez Rodriguez, Paula 
dc.contributor.authorBlasco , MA 
dc.date.accessioned2019-10-02T09:34:43Z
dc.date.available2019-10-02T09:34:43Z
dc.date.issued2017-04-03
dc.identifier.citationJ Cell Biol. 2017;216(4):875-887.es_ES
dc.identifier.issn0021-9525es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/8470
dc.description.abstractTelomeres, the protective ends of linear chromosomes, shorten throughout an individual's lifetime. Telomere shortening is proposed to be a primary molecular cause of aging. Short telomeres block the proliferative capacity of stem cells, affecting their potential to regenerate tissues, and trigger the development of age-associated diseases. Mutations in telomere maintenance genes are associated with pathologies referred to as telomere syndromes, including Hoyeraal-Hreidarsson syndrome, dyskeratosis congenita, pulmonary fibrosis, aplastic anemia, and liver fibrosis. Telomere shortening induces chromosomal instability that, in the absence of functional tumor suppressor genes, can contribute to tumorigenesis. In addition, mutations in telomere length maintenance genes and in shelterin components, the protein complex that protects telomeres, have been found to be associated with different types of cancer. These observations have encouraged the development of therapeutic strategies to treat and prevent telomere-associated diseases, namely aging-related diseases, including cancer. Here we review the molecular mechanisms underlying telomere-driven diseases and highlight recent advances in the preclinical development of telomere-targeted therapies using mouse models.es_ES
dc.description.sponsorshipResearch in the Blasco laboratory is funded by the Spanish Ministry of Economy and Competitiveness and Fondo Europeo de Desarrollo Regional project RET OS (grant SAF2013-45111-R), the European Research Council project TEL STEM CELL (grant ERC-2008-AdG/232854), and Fondacion Botin.es_ES
dc.language.isoenges_ES
dc.publisherRockefeller University Press es_ES
dc.type.hasVersionVoRes_ES
dc.subject.meshAging es_ES
dc.subject.meshAnimals es_ES
dc.subject.meshCell Transformation, Neoplastices_ES
dc.subject.meshChromosomal Instability es_ES
dc.subject.meshDyskeratosis Congenita es_ES
dc.subject.meshFetal Growth Retardation es_ES
dc.subject.meshHumans es_ES
dc.subject.meshIntellectual Disability es_ES
dc.subject.meshMicrocephaly es_ES
dc.subject.meshMolecular Targeted Therapy es_ES
dc.subject.meshMutation es_ES
dc.subject.meshNeoplasms es_ES
dc.subject.meshTelomerase es_ES
dc.subject.meshTelomere es_ES
dc.subject.meshTelomere Homeostasis es_ES
dc.subject.meshTelomere Shortening es_ES
dc.titleTelomere-driven diseases and telomere-targeting therapieses_ES
dc.typejournal articlees_ES
dc.identifier.pubmedID28254828es_ES
dc.format.volume216es_ES
dc.format.number4es_ES
dc.format.page875-887es_ES
dc.identifier.doi10.1083/jcb.201610111es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España) 
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) 
dc.contributor.funderUnión Europea. Comisión Europea. European Research Council (ERC) 
dc.contributor.funderBotín Foundation 
dc.description.peerreviewedes_ES
dc.identifier.e-issn1540-8140es_ES
dc.relation.publisherversionhttps:// 10.1083/jcb.201610111.es_ES
dc.identifier.journalThe Journal of cell biologyes_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de Telómeros y Telomerasaes_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/SAF2013-45111-Res_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/EC/FP7/232854es_ES
dc.rights.accessRightsopen accesses_ES


Files in this item

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record